Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.

Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.

Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.

Amid doubts about early data with FG-3246, the group is scathing about its rivals.

Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.

The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.